Correction: Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5
Metrics: PDF 353 views | ?
1 Molecular Pathology Laboratory, Department of Molecular and Clinical Cancer Medicine, Liverpool University, Liverpool, L3 9TA, United Kingdom
2 Sichuan Antibiotics Industrial Institute, Chengdu University, Chengdu 610081, China
3 Department of Biochemistry, Liverpool University, Liverpool, L69 3GA, United Kingdom
Published: August 04, 2020
This article has been corrected: The following references were accidentally omitted from the published list:
54. Xu M, Joo HJ, Paik YK. Novel functions of lipid-binding protein 5 in Caenorhabditis elegans fat metabolism. J Biol Chem. 2011; 286:28111–8. https://doi.org/10.1074/jbc.M111.227165. [PubMed]
55. Pavese J, Ogden IM, Bergan RC. An orthotopic murine model of human prostate cancer metastasis. J Vis Exp. 2013; e50873. https://doi.org/10.3791/50873. [PubMed]
56. Janik P, Briand P, Hartmann NR. The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. Cancer Res. 1975; 35:3698–704. [PubMed]
57. Thumser AE, Storch J. Characterization of a BODIPY-labeled fluorescent fatty acid analogue. Binding to fatty acid-binding proteins, intracellular localization, and metabolism. Mol Cell Biochem. 2007; 299:67–73. https://doi.org/10.1007/s11010-005-9041-2. [PubMed]
Original article: Oncotarget. 2017; 8:31041–31056. DOI: https://doi.org/10.18632/oncotarget.16055.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.